Search

Charles E. Cooley

Examiner (ID: 18400, Phone: (571)272-1139 , Office: P/1774 )

Most Active Art Unit
1774
Art Unit(s)
1797, 1774, 1723, 2402, 1754, 3405
Total Applications
4063
Issued Applications
3143
Pending Applications
300
Abandoned Applications
659

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 18844511 [patent_doc_number] => 20230406915 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => ANTI-DKK2 ANTIBODY, COMPOSITION CONTAINING ANTI-DKK2 ANTIBODY, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/255567 [patent_app_country] => US [patent_app_date] => 2021-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16386 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18255567 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/255567
ANTI-DKK2 ANTIBODY, COMPOSITION CONTAINING ANTI-DKK2 ANTIBODY, AND USE THEREOF Nov 15, 2021 Pending
Array ( [id] => 18664883 [patent_doc_number] => 11771748 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-03 [patent_title] => Methods for treating tumor-induced osteomalacia [patent_app_type] => utility [patent_app_number] => 17/525738 [patent_app_country] => US [patent_app_date] => 2021-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 30 [patent_no_of_words] => 42346 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17525738 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/525738
Methods for treating tumor-induced osteomalacia Nov 11, 2021 Issued
Array ( [id] => 18808632 [patent_doc_number] => 20230382966 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => NOVEL KLOTHO INTERACTION SITE IN THE C-TERMINUS OF FGF23 [patent_app_type] => utility [patent_app_number] => 18/032479 [patent_app_country] => US [patent_app_date] => 2021-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10488 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18032479 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/032479
NOVEL KLOTHO INTERACTION SITE IN THE C-TERMINUS OF FGF23 Oct 25, 2021 Pending
Array ( [id] => 17520542 [patent_doc_number] => 20220106391 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => ANTI-NGF ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/496597 [patent_app_country] => US [patent_app_date] => 2021-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49031 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17496597 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/496597
ANTI-NGF ANTIBODIES AND METHODS OF USE THEREOF Oct 6, 2021 Abandoned
Array ( [id] => 18770853 [patent_doc_number] => 20230365654 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => METHOD OF TREATMENT OF FIBROSIS AND WOUND HEALING [patent_app_type] => utility [patent_app_number] => 18/030089 [patent_app_country] => US [patent_app_date] => 2021-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6123 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18030089 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/030089
METHOD OF TREATMENT OF FIBROSIS AND WOUND HEALING Oct 3, 2021 Pending
Array ( [id] => 18771145 [patent_doc_number] => 20230365956 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => RECOMBINANT ACE2-FC FUSION MOLECULES AND METHODS OF MAKING AND USING THEREOF [patent_app_type] => utility [patent_app_number] => 18/029043 [patent_app_country] => US [patent_app_date] => 2021-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15462 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18029043 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/029043
RECOMBINANT ACE2-FC FUSION MOLECULES AND METHODS OF MAKING AND USING THEREOF Sep 30, 2021 Pending
Array ( [id] => 18787284 [patent_doc_number] => 20230375552 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => INTEGRATED PROTEOMIC BIOMARKERS FOR THE DETECTION OF AGGRESSIVE PROSTATE CANCER [patent_app_type] => utility [patent_app_number] => 18/247144 [patent_app_country] => US [patent_app_date] => 2021-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18635 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18247144 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/247144
INTEGRATED PROTEOMIC BIOMARKERS FOR THE DETECTION OF AGGRESSIVE PROSTATE CANCER Sep 28, 2021 Pending
Array ( [id] => 18817521 [patent_doc_number] => 20230391861 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => POTENT BINDING AGENTS FOR ACTIVATION OF THE HEDGEHOG SIGNALING PATHWAY [patent_app_type] => utility [patent_app_number] => 18/026546 [patent_app_country] => US [patent_app_date] => 2021-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18951 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18026546 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/026546
POTENT BINDING AGENTS FOR ACTIVATION OF THE HEDGEHOG SIGNALING PATHWAY Sep 26, 2021 Pending
Array ( [id] => 17336037 [patent_doc_number] => 20220002368 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => DUAL FUNCTION PROTEINS COMPRISING FGF21 MUTANT PROTEIN AND PHARMACEUTICAL COMPOSITION COMPRISING SAME [patent_app_type] => utility [patent_app_number] => 17/478628 [patent_app_country] => US [patent_app_date] => 2021-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15801 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17478628 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/478628
DUAL FUNCTION PROTEINS COMPRISING FGF21 MUTANT PROTEIN AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Sep 16, 2021 Abandoned
Array ( [id] => 17336036 [patent_doc_number] => 20220002367 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => LONG-ACTING FGF21 FUSION PROTEINS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME [patent_app_type] => utility [patent_app_number] => 17/478600 [patent_app_country] => US [patent_app_date] => 2021-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10578 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17478600 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/478600
LONG-ACTING FGF21 FUSION PROTEINS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Sep 16, 2021 Abandoned
Array ( [id] => 18753981 [patent_doc_number] => 20230357338 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => FACTOR H FRAGMENT Fc FUSIONS WITH IMPROVED POTENCY AND MANUFACTURABILITY [patent_app_type] => utility [patent_app_number] => 18/245453 [patent_app_country] => US [patent_app_date] => 2021-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20759 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18245453 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/245453
FACTOR H FRAGMENT Fc FUSIONS WITH IMPROVED POTENCY AND MANUFACTURABILITY Sep 14, 2021 Pending
Array ( [id] => 17314500 [patent_doc_number] => 20210403548 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => TREATING VASCULAR DISEASE AND COMPLICATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 17/471702 [patent_app_country] => US [patent_app_date] => 2021-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4128 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17471702 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/471702
TREATING VASCULAR DISEASE AND COMPLICATIONS THEREOF Sep 9, 2021 Pending
Array ( [id] => 17290985 [patent_doc_number] => 20210386824 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => Nucleic Acids Encoding FGF21-Fc Fusion Proteins [patent_app_type] => utility [patent_app_number] => 17/410307 [patent_app_country] => US [patent_app_date] => 2021-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23877 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17410307 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/410307
Fibroblast growth factor-21-Fc fusion proteins Aug 23, 2021 Issued
Array ( [id] => 17387058 [patent_doc_number] => 20220034910 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => BIOMARKERS IN THE SELECTION OF THERAPY OF HEART FAILURE [patent_app_type] => utility [patent_app_number] => 17/403078 [patent_app_country] => US [patent_app_date] => 2021-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31936 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17403078 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/403078
BIOMARKERS IN THE SELECTION OF THERAPY OF HEART FAILURE Aug 15, 2021 Abandoned
Array ( [id] => 18753978 [patent_doc_number] => 20230357334 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => COMPOSITION OF DRUG AND WILD-TYPE CELL-PENETRATING PEPTIDE DERIVATIVE [patent_app_type] => utility [patent_app_number] => 18/021868 [patent_app_country] => US [patent_app_date] => 2021-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11130 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18021868 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/021868
COMPOSITION OF DRUG AND WILD-TYPE CELL-PENETRATING PEPTIDE DERIVATIVE Aug 15, 2021 Pending
Array ( [id] => 18650795 [patent_doc_number] => 20230296630 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => MULTIMARKER PANEL FOR THE ASSESSMENT OF SILENT BRAIN INFARCTS AND COGNITIVE DECLINE [patent_app_type] => utility [patent_app_number] => 18/021021 [patent_app_country] => US [patent_app_date] => 2021-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18498 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18021021 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/021021
MULTIMARKER PANEL FOR THE ASSESSMENT OF SILENT BRAIN INFARCTS AND COGNITIVE DECLINE Aug 11, 2021 Pending
Array ( [id] => 18727122 [patent_doc_number] => 20230341403 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => METHODS AND KITS FOR THE DIAGNOSIS OF LUNG CANCER [patent_app_type] => utility [patent_app_number] => 18/005082 [patent_app_country] => US [patent_app_date] => 2021-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7405 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18005082 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/005082
METHODS AND KITS FOR THE DIAGNOSIS OF LUNG CANCER Jul 13, 2021 Pending
Array ( [id] => 17343698 [patent_doc_number] => 20220010029 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => HYBRIDOMA CELL STRAIN THAT SECRETS ANTI-DINITOLMIDE MONOCLONAL ANTIBODIES AND THE APPLICATION OF HYBRIDOMA CELL STRAIN [patent_app_type] => utility [patent_app_number] => 17/368108 [patent_app_country] => US [patent_app_date] => 2021-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2767 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17368108 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/368108
Anti-dinitolmide monoclonal antibodies and hybridoma cell strain that secretes them Jul 5, 2021 Issued
Array ( [id] => 17343690 [patent_doc_number] => 20220010021 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => FGFR1/KLB Targeting Agonistic Antigen-Binding Proteins and Conjugates Thereof with GLP-1R Agonistic Peptides [patent_app_type] => utility [patent_app_number] => 17/365183 [patent_app_country] => US [patent_app_date] => 2021-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55874 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 552 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17365183 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/365183
FGFR1/KLB targeting agonistic antigen-binding proteins and conjugates thereof with GLP-1R agonistic peptides Jun 30, 2021 Issued
Array ( [id] => 17156125 [patent_doc_number] => 20210317176 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => FG21 MUTANTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/357444 [patent_app_country] => US [patent_app_date] => 2021-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29943 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17357444 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/357444
Methods of treating non-alcoholic steatohepatitis using FGF21 mutants Jun 23, 2021 Issued
Menu